Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179673 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
A Phase 2 study of Non-Hodgkin's Lymphoma, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 15
- Study locations
NCT00179673: Completed Phase 2 study of Non-Hodgkin's Lymphoma, sponsored by Celgene.
NCT00179673 is a Phase 2 study of Non-Hodgkin's Lymphoma that has completed, run by Celgene. The registered enrollment target is 43 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (81% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179673, a Phase 2 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 15
- Study locations
Study Summary
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be followed for progression free survival following discontinuation from the treatment phase
Primary Outcome
Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities. Cru: Criteria for CR above but with 1 or mo
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (15)
California
- Alta Bates Cancer Center - Berkeley
- Pacific Coast Hematology/Oncology Medical Group, Onc. - Fountain Valley
British Columbia
- BC Community Oncology Trialist - Burnaby
- BC Community Oncology - North Vancouver
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Harvard University - Boston
Minnesota
- Mayo Clinic - Rochester
Nebraska
- University of Nebraska - Omaha
New York
- New York Medical Center, MBCCOP - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
What the finished NCT00179673 record still lists
NCT00179673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00179673 lists 15 locations in 13 states (California, British Columbia, Arizona).
Frequently Asked Questions
What is clinical trial NCT00179673 about?
NCT00179673 is a clinical study titled "Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma". Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be ...
What is the current status of trial NCT00179673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2005-06. Estimated completion is 2008-04.
What conditions does trial NCT00179673 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00179673?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00179673?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179673 being conducted?
This trial has 15 study locations across Arizona, California, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00179673's enrollment target sits among peer trials
43 33rd of 63 higher than 31 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia